Yuan-Li Shen

7PUBLICATIONS
77CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Major global burdens of diseaseSpatial data and applicationsMolecular targetsAvionics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 01, 2026
FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma.

|Sep 08, 2025
Decentralized Clinical Trials in the Era of Real-World Evidence: A Critical Assessment of Recent Experiences.

Hongwei Wang, Nadia Daizadeh, Yuan-Li Shen

|Feb 19, 2025
Decentralized Clinical Trials in the Era of Real-World Evidence: A Statistical Perspective.

Jie Chen, Junrui Di, Nadia Daizadeh

|Sep 07, 2023
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.

Timil H Patel, Jamie R Brewer, Jiaxin Fan

|Aug 25, 2023
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.

Sonia Singh, Diana Bradford, Xiaoxue Li

|Jun 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer.

Sandra J Casak, M Naomi Horiba, Mengdie Yuan

Pageof 2

Frequent Collaborators

4 joint publications

Richard Pazdur

3 joint publications

Jiang Liu

3 joint publications

Paul G Kluetz

2 joint publications

Lola A Fashoyin-Aje